Here are three reasons why there are better opportunities than INCY and a stock we'd rather own. Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The company’s shares closed yesterday at $62.01.

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (BMV:INCY) from Outperform to Market Perform. There are 1,211 funds or institutions reporting positions in ...

Even though the stock has become cheaper, we don't have much confidence in Incyte. Here are three reasons why there are better opportunities than INCY and a stock we'd rather own. Founded in 1991 and ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

“Spider-Man: Beyond the Spider-Verse,” the third entry in Sony’s animated web-slinging trilogy, will swing into theaters… in a few years. It’ll be released on June 4, 2027. “We know ...

Peter Parker’s next cinematic outing is officially titled “Spider-Man: Brand New Day.” The fourquel will begin filming this summer, according to director Destin Daniel Cretton, who announced ...

Incyte (NASDAQ:INCY) recently announced that it had achieved positive results from both of its phase 3 studies STOP-HS1 and STOP-HS2. Both of these late-stage studies were using the company's drug ...